Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBT Margin (2020 - 2025)

Historic EBT Margin for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to 13180.5%.

  • Silence Therapeutics' EBT Margin fell 108110100.0% to 13180.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 248.57%, marking a year-over-year increase of 1187000.0%. This contributed to the annual value of 102.79% for FY2024, which is 655700.0% up from last year.
  • Silence Therapeutics' EBT Margin amounted to 13180.5% in Q3 2025, which was down 108110100.0% from 12207.14% recorded in Q2 2025.
  • Silence Therapeutics' EBT Margin's 5-year high stood at 49.9% during Q4 2024, with a 5-year trough of 313931.3% in Q1 2021.
  • Its 5-year average for EBT Margin is 19339.42%, with a median of 368.38% in 2022.
  • In the last 5 years, Silence Therapeutics' EBT Margin surged by 2000000000bps in 2021 and then plummeted by -200783800bps in 2025.
  • Silence Therapeutics' EBT Margin (Quarter) stood at 328.85% in 2021, then increased by 4bps to 315.84% in 2022, then tumbled by -126bps to 713.01% in 2023, then soared by 107bps to 49.9% in 2024, then tumbled by -26516bps to 13180.5% in 2025.
  • Its last three reported values are 13180.5% in Q3 2025, 12207.14% for Q2 2025, and 20091.55% during Q1 2025.